Top Page
Aquestive Therapeutics
(NASDAQ:AQST)
Aquestive Therapeutics (AQST) vs. SPDR S&P 500 ETF (SPY)
Aquestive Therapeutics Business Overview & Revenue Model
Aquestive Therapeutics Earnings Call Summary
Aquestive Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 43.40M | 57.56M | 50.58M | 47.68M | 50.83M | 45.85M |
| Gross Profit | 26.16M | 39.69M | 29.75M | 28.29M | 35.84M | 32.88M |
| EBITDA | -48.63M | -26.62M | 1.18M | -39.58M | -45.11M | -39.15M |
| Net Income | -68.98M | -44.14M | -7.87M | -54.41M | -70.54M | -55.78M |
Balance Sheet | ||||||
| Total Assets | 163.56M | 101.42M | 57.42M | 57.07M | 61.99M | 62.88M |
| Cash, Cash Equivalents and Short-Term Investments | 129.06M | 71.55M | 23.87M | 27.27M | 28.02M | 31.81M |
| Total Debt | 128.86M | 38.00M | 33.32M | 57.49M | 56.42M | 40.48M |
| Total Liabilities | 167.67M | 161.58M | 163.91M | 175.62M | 144.13M | 111.38M |
| Stockholders Equity | -4.11M | -60.16M | -106.49M | -118.55M | -82.13M | -48.50M |
Cash Flow | ||||||
| Free Cash Flow | -50.94M | -35.92M | -7.38M | -12.31M | -33.89M | -45.98M |
| Operating Cash Flow | -50.45M | -35.76M | -6.38M | -9.79M | -32.98M | -45.46M |
| Investing Cash Flow | -492.00K | -159.00K | -995.00K | -2.52M | -913.00K | -517.00K |
| Financing Cash Flow | 102.11M | 83.59M | 3.97M | 11.56M | 30.11M | 28.46M |
Aquestive Therapeutics Technical Analysis
Aquestive Therapeutics Risk Analysis
Aquestive Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $582.87M | 7.09 | 39.94% | ― | -0.85% | -13.50% | |
67 Neutral | $519.42M | 7.64 | 13.92% | ― | -29.91% | ― | |
60 Neutral | $651.06M | ― | 0.30% | ― | 2.24% | -67.56% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $674.16M | ― | ― | ― | 2.83% | 13.61% | |
49 Neutral | $450.50M | ― | ― | ― | 15.10% | 0.18% | |
41 Neutral | $710.06M | ― | ― | ― | -26.32% | -56.54% |
Aquestive Therapeutics Corporate Events
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on developing innovative medicines using advanced delivery technologies to improve patient outcomes, particularly in the field of orally administered therapies for complex molecules. The company is actively working on expanding its product pipeline and commercializing its proprietary products.
Aquestive Therapeutics, Inc. recently held an earnings call that highlighted a mix of optimism and challenges. The company expressed positive sentiment regarding its strategic progress towards the FDA approval of Anaphylm and significant financing achievements. However, financial challenges such as an increased net loss and decreased revenue underscore ongoing operational hurdles.
Aquestive Therapeutics has announced updates regarding its product pipeline, particularly the advancement of Anaphylm (dibutepinephrine) Sublingual Film and other candidates like AQST-108 and Libervant. The company is working towards FDA approval and international market entry, with potential implications for its market positioning and stakeholder interests, contingent on overcoming regulatory and competitive challenges.
The most recent analyst rating on (AQST) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Aquestive Therapeutics reported its third quarter 2025 financial results and provided a business update, highlighting preparations for the potential U.S. launch of Anaphylm, a needle-free oral medication for severe allergic reactions, pending FDA approval in early 2026. The company also advanced its regulatory activities for Anaphylm in Canada and the EU, expanded its patent estate, and continued developing its product pipeline, including a topical gel for alopecia areata. Financially, the company saw a 4% year-over-year revenue increase excluding deferred revenue impacts, despite a net loss of $15.4 million due to higher commercial and regulatory expenses.
The most recent analyst rating on (AQST) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
On October 8, 2025, Aquestive Therapeutics announced the issuance of two new U.S. patents for Anaphylm™, a novel epinephrine prodrug sublingual film, extending its protection until 2037. This development is significant as Anaphylm, if approved by the FDA, will be the first oral medication for severe allergic reactions, providing a needle-free alternative to epinephrine injections, thus potentially impacting the treatment landscape for anaphylaxis.
The most recent analyst rating on (AQST) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Aquestive Therapeutics announced plans for the advancement of its product candidate Anaphylm, a sublingual film for epinephrine administration, through clinical development and potential FDA approval. The company is also progressing with its Adrenaverse pipeline, including AQST-108 for alopecia areata, and preparing for the commercial launch of Libervant, highlighting potential market growth and revenue opportunities.
The most recent analyst rating on (AQST) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
On September 8, 2025, Aquestive Therapeutics presented an investor presentation at the H.C. Wainwright 27th Annual Global Investor Conference. The presentation highlighted the company’s progress with its product candidates, including Anaphylm and AQST-108, and discussed potential market opportunities and regulatory challenges. The company aims to position Anaphylm as a novel oral administration of epinephrine, pending FDA approval, and anticipates growth in the U.S. epinephrine market. However, the company faces risks related to regulatory approvals, market acceptance, and financial resources.
The most recent analyst rating on (AQST) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
On September 4, 2025, Aquestive Therapeutics announced that the FDA will not require an advisory committee meeting for their new drug application for Anaphylm™, a sublingual film for severe allergic reactions. This decision keeps the Prescription Drug User Fee Act target action date on track for January 31, 2026, potentially making Anaphylm the first FDA-approved, non-invasive epinephrine product. The company is preparing for a rapid launch upon approval, supported by recent financing activities, which could significantly impact the treatment landscape for anaphylaxis by offering a needle-free alternative.
The most recent analyst rating on (AQST) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Aquestive Therapeutics’ recent earnings call painted a picture of both optimism and caution. The company is making significant strides in the development and pre-launch activities for its promising product, Anaphylm, which could open up substantial market opportunities. However, financial hurdles such as declining revenues and increased net losses, coupled with market access challenges, remain pressing concerns for the company.
On August 14, 2025, Aquestive Therapeutics announced an underwriting agreement for an offering of 21,250,000 shares of common stock at $4.00 per share, expected to raise $85 million. The proceeds will primarily fund the launch and commercialization of Anaphylm™, a sublingual film for severe allergic reactions, pending FDA approval, and support the company’s operations into 2027.
The most recent analyst rating on (AQST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
On August 13, 2025, Aquestive Therapeutics announced a $75 million strategic funding agreement with RTW Investments, contingent upon FDA approval of Anaphylm, a sublingual film for treating severe allergic reactions. This financing aims to support the potential commercialization of Anaphylm, strengthening the company’s financial position and offering a novel treatment option for patients. The agreement includes tiered revenue share payments to RTW based on Anaphylm’s net sales in the U.S., with payments ceasing upon reaching specified financial thresholds.
The most recent analyst rating on (AQST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on developing innovative, orally administered products to improve patient care, particularly in the treatment of severe allergic reactions and other medical conditions. The company is known for its proprietary delivery technologies and collaborations with other pharmaceutical firms.
Aquestive Therapeutics announced its second quarter 2025 financial results and business updates, highlighting the FDA’s acceptance of their New Drug Application for Anaphylm, a sublingual film epinephrine product. The company is preparing for a potential U.S. launch in 2026 and is also pursuing regulatory engagements in Canada and the EU. Aquestive aims to address unmet needs in emergency allergy treatment with Anaphylm, which offers advantages over existing epinephrine therapies. Financially, the company reported a net loss of $13.5 million for the second quarter of 2025, attributed to decreased revenues and increased expenses.
The most recent analyst rating on (AQST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.